Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29699726 | 0.86 | HPGD (0.49) | HPGDESR1ESR2MEN1KMT2A | |
| SCHEMBL5199329 | 0.86 | HPGD (0.49) | HPGDESR1ESR2MEN1KMT2A | |
| SCHEMBL1827702 | 0.85 | HPGD (0.48) | HPGDESR1ESR2MEN1KMT2A | |
| SCHEMBL21635118 | 0.83 | MEN1 (0.44) | HPGDESR1ESR2MEN1KMT2A | |
| SCHEMBL3663090 | 0.82 | CYP4F2 (0.42) | HPGDCES2CES1ALDH1A1 | |
| SCHEMBL17905129 | 0.81 | HPGD (0.46) | HPGDMEN1KMT2AATMPPARG | |
| SCHEMBL17980515 | 0.81 | CYP3A4 (0.48) | MEN1KMT2AALDH1A1 | |
| SCHEMBL16099852 | 0.81 | PARP1 (0.50) | ESR1ESR2MEN1KMT2APARP1 | |
| SCHEMBL10436347 | 0.81 | CYP3A4 (0.61) | ESR1ESR2MEN1KMT2AATM | |
| SCHEMBL4431821 | 0.81 | LMNA (0.61) | MEN1KMT2APPARGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3374520-A1 | BIOSENSORS | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2018-09-19 | — | — | EP | claimed |
| WO-2017081684-A1 | BIOSENSORS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2017-05-18 | — | — | WO | claimed |
| US-6232305-B1 | ANTICANCER AGENTS; BONE DISORDERS; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS | NAEJA PHARMACEUTICAL INC. (CA) | 2001-05-15 | — | — | US | claimed |
| EP-0961779-A1 | SUBSTITUTED AMINO BICYCLIC-$g(b)-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | SYNPHAR LABORATORIES INC. (CA) | 1999-12-08 | — | — | EP | claimed |
| WO-1998032766-A1 | SUBSTITUTED AMINO BICYCLIC-β-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | SYNPHAR LABORATORIES INC. (US) | 1998-07-30 | — | — | WO | claimed |
| US-12428455-B2 | Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250223328-A1 | TRUNCATED DOMINANT NEGATIVE CEBPB AND CEBPD PROTEINS AND METHODS OF USE FOR DECREASING VIABILITY OF NEOPLASTIC CELLS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2025-07-10 | — | — | US | disclosed |
| CN-113396218-B | Engineered transaminase polypeptides | 科德克希思公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2024086775-A2 | TRUNCATED DOMINANT NEGATIVE CEBPB AND CEBPD PROTEINS AND METHODS OF USE FOR DECREASING VIABILITY OF NEOPLASTIC CELLS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20210163551-A1 | DOMINANT NEGATIVE CEBPB AND CEBPD PROTEINS AND METHODS OF USE FOR DECREASING VIABILITY OF NEOPLASTIC CELLS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2021-06-03 | — | — | US | disclosed |
| WO-2020033555-A2 | DOMINANT NEGATIVE CEBPB AND CEBPD PROTEINS AND METHODS OF USE FOR DECREASING VIABILITY OF NEOPLASTIC CELLS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-02-13 | — | — | WO | disclosed |
| CN-110078811-A | A kind of polypeptide IMB-P1 with anti-tumor activity and its application | 中国医学科学院医药生物技术研究所 | 2019-08-02 | — | — | CN | disclosed |
| WO-2005123686-A1 | HETEROCYCLIC DERIVATIVES FOR TREATMENT OF HYPERLIPIDEMIA AND RELATED DISEASES | AVANIR PHARMACEUTICALS (US) | 2005-12-29 | — | — | WO | disclosed |
| US-6271238-B1 | USEFUL IN TREATING AND PREVENTING DISEASES INVOLVING CHYMOTRYPSIN TYPE PROTEASES WHICH ARE RELATED TO ASTHMA, ALLERGY, INFLAMMATIONS, RHEUMATISM, HYPERTENSION, HEART FAILURE, MYOCARDIAL INFARCTION, AND CARDIAC HYPERTROPHY | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-08-07 | — | — | US | disclosed |
| EP-0936216-A1 | NOVEL ACETAMIDE DERIVATIVES AND PROTEASE INHIBITORS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1999-08-18 | — | — | EP | disclosed |
| EP-0787116-A1 | PROCESS FOR SEPARATING ENANTIOMERS FROM A RACEMIC MIXTURE | Akzo Nobel N.V. (NL) | 1997-08-06 | — | — | EP | disclosed |
| EP-0663897-B1 | PROCESS FOR SEPARATING ENANTIOMERS FROM A RACEMIC MIXTURE | AKZO NOBEL NV (NL) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996011894-A1 | PROCESS FOR SEPARATING ENANTIOMERS FROM A RACEMIC MIXTURE | AKZO NOBEL N.V. (NL) | 1996-04-25 | — | — | WO | disclosed |
| EP-0663897-A1 | PROCESS FOR SEPARATING ENANTIOMERS FROM A RACEMIC MIXTURE. | AKZO NOBEL NV (NL) | 1995-07-26 | — | — | EP | disclosed |
| WO-1994007814-A1 | PROCESS FOR SEPARATING ENANTIOMERS FROM A RACEMIC MIXTURE | AKZO NOBEL N.V. (NL) | 1994-04-14 | — | — | WO | disclosed |